Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

Citation
F. Suzuki et al., Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen, J GASTRO, 36(4), 2001, pp. 242-247
Citations number
12
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Gastroenerology and Hepatology
Journal title
JOURNAL OF GASTROENTEROLOGY
ISSN journal
0944-1174 → ACNP
Volume
36
Issue
4
Year of publication
2001
Pages
242 - 247
Database
ISI
SICI code
0944-1174(200104)36:4<242:TAOIFC>2.0.ZU;2-C
Abstract
Purpose. Although interferon (IFN) is commonly used for the treatment of ch ronic hepatitis C virus (HCV) infection, eradication of the virus occurs in only a small proportion of patients with genotype Ib and a high virus tite r. Modified IFN therapies have been tried, with only limited benefit. Recen tly the administration of IFN-beta twice per day has been reported to be mo re effective than the usual once-daily administration regimen. The aim of t his study was to evaluate whether twice-daily IFN results in a sustained re sponse in patients with chronic HCV infection with genotype Ib and a high v irus titer. Methods. Twenty patients with genotype Ib and high HCV RNA leve l (more than 1 MEq/ml by branched DNA probe assay) were randomly assigned t o receive either twice-daily 3 MU of IFN beta (group A) or once-daily 6 MU of IFN-beta (group B) for 4 weeks. All patients received a further daily do se of 6 MU IFN-beta for 12 weeks, followed by IFN-alfa three times a week f or 16 weeks. Results, Although a rapid fall in HCV RNA levels was noted in group At a sustained response was observed in only one of nine patients in this group, and none of group B. Adverse effects of IFN were more frequent and pronounced in group A than in group B, Conclusions We conclude that fur ther modification, which combines the early strong anti-viral effects of th e twice-daily regimen with long-term sustained response, is necessary for e ffective therapy of HCV patients with genotype `b and high HCV RNA levels.